Evidence map›Paper›PMID 40891129›Full record

ReviewNanomedicine (London, England)2025

Biological properties of ceragenin-coated metal nanoparticles - future challenges and perspectives in clinical practice.

Piotr Bijak, Ewelina Piktel, Wiesława Niklinska, Tamara Daniluk, Paulina Paprocka, Grzegorz Król, Paul B Savage, Robert Bucki

Abstract readReview
In one paragraph

Review in Nanomedicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Piotr BijakDepartment of Medical Microbiology and Nanobiomedical Engineering, Medical University of Białystok, Białystok, Poland.
Ewelina PiktelIndependent Laboratory of Nanomedicine, Medical University of Białystok, Białystok, Poland.
Wiesława NiklinskaDepartment of Histology and Embryology, Medical University of Białystok, Białystok, Poland.
Tamara DanilukDepartment of Medical Microbiology and Nanobiomedical Engineering, Medical University of Białystok, Białystok, Poland.
Paulina PaprockaInstitute of Medical Science, Collegium Medicum, Jan Kochanowski University in Kielce, Kielce, Poland.
Grzegorz KrólInstitute of Medical Science, Collegium Medicum, Jan Kochanowski University in Kielce, Kielce, Poland.
Paul B SavageDepartment of Chemistry and Biochemistry, Brigham Young University, Provo, UT, USA.
Robert BuckiDepartment of Medical Microbiology and Nanobiomedical Engineering, Medical University of Białystok, Białystok, Poland.

Funding

Medical University of Białystok
6 · The paper itself

Abstract

Considering the priority of searching for new therapeutic strategies related to increasing microbial resistance and complex needs of oncological treatment, the potential of ceragenin-coated metal nanoparticles (primarily in the form of core-shell nanosystems) as tools for developing new treatment methods was discussed. In particular, the complex mechanisms of action of the ceragenin-containing nanosystems were described, and the presented actions were compared with the native efficacy of ceragenins. The methods for their synthesis and characterization, taking into account features such as size, shape, surface charge, and colloidal stability, were also presented. The synergy of this combination is a potentially effective alternative for combating multidrug-resistant strains of bacteria, as well as fungi. This is also crucial when counteracting the biofilms forming on the surfaces of implants, catheters, or endotracheal tubes. When applying for cancer therapies, the employment of modified ceragenin nanosystems as targeted drug delivery systems may help achieve higher drug concentrations in the tumor environment as well as lower systemic toxicity compared to current therapeutic methods. The collected data justify the need for further studies to fully assess the safety and therapeutic efficacy of ceragenin-containing nanosystems, which will certainly translate into the development of innovative therapeutic methods.

Indexed as

Metal NanoparticlesNeoplasmsSteroidsAnimalsAntineoplastic AgentsDrug Delivery SystemsHumansAntineoplastic AgentsSteroidsantimicrobial therapycancer treatmentCerageninscore-shell nanosystemsdrug-resistant infectionsmetallic nanoparticles

Identifiers

PMID40891129
PMCPMC12505520

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.